insulin glargine
Drug ingredientThis chemical is an active pharmaceutical ingredient used in FDA-regulated drugs.
Where It Comes From
11 FDA-registered drug labelers
A-S Medication Solutions
Amphastar Nanjing Pharmaceuticals, Inc.
Biocon Biologics Inc.
Biocon Limited
Civica, Inc.
Eli Lilly and Company
Eli Lilly Italia SPA
Hefei Xinzhu Biological Technology Co., Ltd.
Lilly France
Professional Complementary Health Formulas
Sanofi-Aventis U.S. LLC
Why It Matters
Sectors
Health
Downstream Uses
Appears in 14 drug and cosmetic product listings (FDA).
- •Insulin Glargine
- •Basaglar Tempo Pen
- •Rezvoglar KwikPen
- •Soliqua 100/33
- •Lantus
- •Toujeo Max
- •Semglee
- •Toujeo
Show all 14
- •Insulin glargine U-300
- •Insulin 1556
- •Insulin glargine U-300 Max
- •Basaglar KwikPen
- •Lantus Solostar
- •Insulin Glargine Solostar
FDA Shortage Status
Whether any manufacturer currently reports this drug as in shortage on the FDA Drug Shortages database. "Active Shortage" means at least one presentation has status "current."
No Shortage
Shortage History
Each row is a separate manufacturer's FDA shortage filing — not a timeline for the drug as a whole. Multiple "current" entries are normal: each manufacturer/NDC files independently. Status reflects the manufacturer's report; reason describes their supply situation (Available, Unavailable, or to be discontinued).
to be discontinued
Insulin Glargine Injection
10/24/2025Chemical Identity
CAS160337-95-1
PubChem CID118984454
DTXSIDDTXSID0043927
FormulaC267H404N72O78S6
Mol. Weight6063 g/mol
SMILESCCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN
Data Sources
1189844542026-04-07
https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/insulin glargine/cids/JSON
Archive: data/sources/pubchem_name/insulin glargine.json
CAS 160337-95-12026-04-25
https://open.fda.gov/data/ndc/
Archive: data/sources/fda/ndc/ndc.json
CAS 160337-95-12026-06-13
https://api.fda.gov/drug/shortages.json
Archive: data/sources/fda/shortages/shortages.json